Pharmaceutical

EC approves BMS’ nivolumab SC formulation for solid tumours

The EC has granted approval for the new subcutaneous (SC) formulation of Bristol Myers Squibb’s (BMS) Opdivo (nivolumab)

May 30, 2025 - 06:00
EC approves BMS’ nivolumab SC formulation for solid tumours
The EC has granted approval for the new subcutaneous (SC) formulation of Bristol Myers Squibb’s (BMS) Opdivo (nivolumab)
Read the original article

Tags:

Previous Article

FDA approves Eton’s application for hydrocortisone oral solution

Next Article

ASCO25: Merck KGaA to seek approval of TGCT drug after Phase III success

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Beta Bionics’ automated insulin delivery system picks up manufacturing partner

Beta Bionics’ automated insulin delivery system picks u...

May 26, 2023

Vertex’s stock hurt after non-opioid pain drug shows benefit similar to placebo

Vertex’s stock hurt after non-opioid pain drug shows be...

Dec 21, 2024

Rejuvenate and SAS partner to harness AI for age-related diseases

Rejuvenate and SAS partner to harness AI for age-relate...

Aug 3, 2024